Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 18.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,337 shares of the company’s stock after acquiring an additional 662 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in NewAmsterdam Pharma were worth $79,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of NAMS. RA Capital Management L.P. grew its stake in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after acquiring an additional 1,293,938 shares in the last quarter. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 53.0% during the first quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock valued at $72,504,000 after acquiring an additional 1,226,852 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in NewAmsterdam Pharma by 85.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,950,650 shares of the company’s stock valued at $39,930,000 after acquiring an additional 900,650 shares in the last quarter. Duquesne Family Office LLC grew its stake in shares of NewAmsterdam Pharma by 178.4% in the 1st quarter. Duquesne Family Office LLC now owns 800,360 shares of the company’s stock worth $16,383,000 after buying an additional 512,825 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of NewAmsterdam Pharma by 20.7% in the 1st quarter. Alliancebernstein L.P. now owns 2,241,953 shares of the company’s stock worth $45,893,000 after buying an additional 383,888 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Royal Bank Of Canada boosted their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a “buy” rating and a $42.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a “neutral” rating and a $27.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

NewAmsterdam Pharma Trading Up 12.2%

NAMS stock opened at $37.05 on Monday. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $37.07. The company has a 50-day moving average price of $26.37 and a 200 day moving average price of $21.63. The stock has a market cap of $4.17 billion, a PE ratio of -22.87 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The firm had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $1.44 million. Sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at approximately $387,450. The trade was a 90.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper purchased 1,260 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average cost of $24.99 per share, with a total value of $31,487.40. Following the completion of the purchase, the director owned 3,027,864 shares in the company, valued at $75,666,321.36. This trade represents a 0.04% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 2,391 shares of company stock valued at $58,424 and sold 324,954 shares valued at $7,844,906. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.